On February 28, 2023, Goldman Sachs upgraded their outlook for Krystal Biotech from Neutral to Buy.
Analyst Price Forecast Suggests 33.56% Upside
As of March 2, 2023, the average one-year price target for Krystal Biotech is $109.40. The forecasts range from a low of $79.79 to a high of $139.65. The average price target represents an increase of 33.56% from its latest reported closing price of $81.91.
The projected annual revenue for Krystal Biotech is $42MM. The projected annual non-GAAP EPS is -$4.84.
What are Large Shareholders Doing?
FBIOX - Biotechnology Portfolio holds 2,106K shares representing 8.18% ownership of the company. No change in the last quarter.
Redmile Group holds 1,897K shares representing 7.37% ownership of the company. In it's prior filing, the firm reported owning 1,900K shares, representing a decrease of 0.15%. The firm increased its portfolio allocation in KRYS by 19.68% over the last quarter.
Avoro Capital Advisors holds 1,410K shares representing 5.48% ownership of the company. In it's prior filing, the firm reported owning 1,275K shares, representing an increase of 9.57%. The firm increased its portfolio allocation in KRYS by 1.67% over the last quarter.
Lord, Abbett & Co. holds 1,278K shares representing 4.96% ownership of the company. In it's prior filing, the firm reported owning 1,212K shares, representing an increase of 5.17%. The firm decreased its portfolio allocation in KRYS by 99.88% over the last quarter.
Frazier Life Sciences Management holds 1,000K shares representing 3.88% ownership of the company. In it's prior filing, the firm reported owning 1,018K shares, representing a decrease of 1.87%. The firm decreased its portfolio allocation in KRYS by 9.91% over the last quarter.
What is the Fund Sentiment?
There are 358 funds or institutions reporting positions in Krystal Biotech. This is an increase of 11 owner(s) or 3.17% in the last quarter. Average portfolio weight of all funds dedicated to KRYS is 0.26%, an increase of 15.01%. Total shares owned by institutions increased in the last three months by 1.90% to 22,977K shares. The put/call ratio of KRYS is 0.95, indicating a bullish outlook.
Krystal Biotech Background Information
(This description is provided by the company.)
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
